Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
about
Low dose versus high dose stavudine for treating people with HIV infectionBeyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)Conducting clinical research in community mental health settings: Opportunities and challengesA review of pharmaceutical labeling for overdose treatment and toxicity data.Patient adherence to prescribed antimicrobial drug dosing regimens.Pharmacogenetics in drug regulation: promise, potential and pitfalls.Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern.Hormesis pervasiveness and its potential implications for pharmaceutical research and development.Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.Can pharmacogenetics help rescue drugs withdrawn from the market?Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.Differences between Japan and the United States in dosages of drugs recently approved in Japan.Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union.Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan.Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects.Clinical pharmacists save thousands of lives: big decrease in dose-related adverse effects.Testing effect of a drug using multiple nested models for the dose-response.Is bigger better? An argument for very low starting doses.Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa.The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.How celecoxib could be safer, how valdecoxib might have been.Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan.Methods for measuring, enhancing, and accounting for medication adherence in clinical trials.Integrating data from the IMPD/IB. A new tool for translational integration of preclinical effects.Integrating dose estimation into a decision-making framework for model-based drug development.1st DIA Annual Japan Workshop for Pharmacogenomics in Tokyo.When less is more - efficacy with less toxicity at the ED50.Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
P2860
Q24186488-B1F69B92-C02E-4FA5-B370-502E8E5DB648Q24795084-39AF9E19-8F00-4D6F-836A-49F1F380B860Q27024400-F35C3ABE-8E21-4240-A932-BB8DDF4E8005Q30584220-057EE33A-C259-4315-9F66-913E322C9853Q34403660-1E762BE9-4775-4CDD-9E00-78AEF0DC965FQ35038052-F1D4A108-08A9-43FD-8AFD-A5209C7C001CQ35236510-C29C9F52-6D7B-4D04-A3D4-644052EEDC2DQ35270130-6340D71D-8D09-449D-A46B-2D7D949E003DQ35826495-0F17639E-67EE-42BE-B98D-5A2AB5176DCEQ36040772-D08DC05A-E33B-4BC9-B197-F96615E62011Q36063631-518ADFC3-547D-4D4A-847D-F1107ED0AFD4Q36596713-A233AF97-AAB3-458F-94B5-762E7194D8A3Q36765799-1651E208-525A-4679-B3DB-7723C0A3A6E1Q36905575-9B6F6632-E746-4FA3-9171-AB96BFAE8142Q37772373-33324EC6-FBE1-490D-9C3C-2308E50B01B5Q37952075-1D8988E2-4DC8-4813-B49E-8F98BEF08C26Q38379186-424AE4DB-FB76-4266-9A40-300068D0DAE1Q38771635-FECFABBE-7385-4650-B286-1C069AE37D31Q39216643-049CCEB9-5540-486A-9A34-6A24508D9C9DQ39314765-15BDF9E6-4BC9-4E68-8CEF-9AC78E17CB92Q40522654-95B54F96-6174-4178-93BE-53525543F634Q41466800-AC13F4D0-979A-4F1E-8AAF-969978FDA4CBQ41677088-EC69FF17-ACA1-4489-9E09-0A4FEA962794Q42249532-3C8F51ED-621D-43E8-85D1-57522FD85F5EQ43932577-4457216A-CFD3-4DF5-AFA9-8E74BB5C0FCAQ46138266-E18BBF61-8D14-4C35-80FA-B4FF38578293Q46479045-C83E9E99-6A68-4EEE-B41C-FCE932181AD4Q46630774-25343E7D-8465-4301-927F-8FF4AE89C5F7Q48142607-87137486-0390-4B16-880E-08135C6CEE62Q48263903-FC2DBE36-7526-4108-BABC-8ECD740263E4Q50761090-88F1C148-C2B2-4052-AFE4-5A05BEE5E1B6Q53371671-C1F011F0-7093-4DAA-BA3C-91939C5ACB90Q56828560-3B34BF05-783B-4182-AA7C-BF6ECEEECB4B
P2860
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@ast
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@en
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@nl
type
label
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@ast
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@en
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@nl
prefLabel
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@ast
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@en
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@nl
P2093
P2860
P356
P1476
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
@en
P2093
Agnes Westelinck
Charles Grudzinskas
Howard Lee
James Cross
Julie Nelson
P2860
P304
P356
10.1002/PDS.744
P577
2002-09-01T00:00:00Z